Compare Novartis AG (NVS) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Raymond James Financial, Inc. — how do they compare? Novartis AG trades at $142.94 (market cap $268.57B), while Raymond James Financial, Inc. trades at $158.57 (market cap $30.51B). The key difference: Novartis AG is far larger — about 8.8× Raymond James Financial, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Raymond James Financial, Inc. for 74 Days on average.
| NVS | RJF | |
|---|---|---|
Market Cap | $268.57B | $30.51B |
Volume | 1,532,573 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $168.62 | $181.18 |
52-Week Low | $121.80 | $140.89 |
Typical Hold Time | 82 Days | 74 Days |
Enterprise Value | $309.89B | $24.37B |
Dividend Yield | 3.31% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Raymond James Financial (RJF) trades at $157.29, down 1.4% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 forecast. Revenue growth is steady, reaching $13.84 billion in 2025, while profitability remains strong with a net income margin of 15.37%. Recent corporate news includes executive leadership appointments and a declared quarterly dividend of $0.54 per share.
The outlook is mixed, with a consensus analyst price target of $184.00 suggesting upside potential, but technical indicators signal near-term caution. Key risks include rising expenses and capital market volatility. The absence of sell ratings and solid institutional interest support a fundamentally sound investment case, though investors should weigh the bearish technical momentum against strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
